Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
19 - Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
from Section 3 - Alzheimer’s Disease Clinical Trials
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Statistical issues are prominent in Alzheimer’s disease (AD) clinical trials due to the enormous challenges in this disease. The complexity of the disease and intervention pathways challenge drug discovery efforts, but measurement and analysis complexities and subjective outcomes also interfere with successful drug development. Variability across disease stage, disease sub-types, comorbidities and concomitant treatments (between-subject), and non-equivalent forms, good and bad days, and rater inconsistencies (within-subject) increase the chance of failure. AD-specific statistical expertise is critical for success, in contrast to most disease areas that require less disease-specific statistical knowledge. Use of global statistical tests and composites, correcting for covariates, and model selection increase the chance of a clearly positive outcome for active treatments and a clearly negative outcome for inactive or harmful treatments.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 232 - 248Publisher: Cambridge University PressPrint publication year: 2022
References
Boada, M, López, OL, Olazarán, J, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease: primary results of the AMBAR study. Alzheimers Dement 2020; 16: 1412–25. https://doi.org/10.1002/alz.12137.CrossRefGoogle ScholarPubMed
Kivipelto, M, Mangialasche, F, Ngandu, T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol 2018; 14: 653–66. https://doi.org/10.1038/s41582-018-0070-3.CrossRefGoogle ScholarPubMed
Cummings, J, Ballard, C, Tariot, P, et al. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis 2018; 5: 253–8. https://doi.org/10.14283/jpad.2018.29.Google Scholar
Huang, P, Goetz, CG, Woolson, RF, et al. Using global statistical tests in long-term Parkinson’s disease clinical trials. Mov Disord 2009; 24: 1732–9. https://doi.org/10.1002/mds.22645.CrossRefGoogle ScholarPubMed
Dickson, SP. Comparison of aducanumab, solanezumab and BAN2401 using a global statistical test for assessing impact on overall strength of evidence. 13th Clinical Trials on Alzheimer’s Disease (CTAD) Congress, November 4–7, 2020.Google Scholar
Schneider, LS, Goldberg, TE. Composite cognitive and functional measures for early stage Alzheimer’s disease trials. Alzheimers Dement Diagnosis, Assess Dis Monit 2020; 12: 1–9. https://doi.org/10.1002/dad2.12017.Google ScholarPubMed
Hendrix, SB, Dickson, SP, Ellison, N. Composite endpoints – pro perspective: the key to successful clinical development in Alzheimer’s disease. Alzheimers Dement 2019; 15: P1274. https://doi.org/10.1016/j.jalz.2019.06.3660.Google Scholar
Hendrix, SB, Ellison, N. ADCOMS: a sensitive measure of disease progression in early AD supporting better development decisions. Alzheimers Dement 2019; 15: P520. https://doi.org/10.1016/j.jalz.2019.06.4426.Google Scholar
Wang, J, Logovinsky, V, Hendrix, SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry 2016; 87: 993–9. https://doi.org/10.1136/jnnp-2015-312383.CrossRefGoogle ScholarPubMed
Wessels, AM, Siemers, ER, Yu, P, et al. A combined measure of cognition and function for clinical trials: the Integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers Dis 2015; 2: 227–41. https://doi.org/10.14283/jpad.2015.82.Google Scholar
Langbaum, JB, Ellison, NN, Caputo, A, et al. The Alzheimer’s Prevention Initiative Composite Cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease. Alzheimers Res Ther 2020; 12: 1–11. https://doi.org/10.1186/s13195-020-00633-2.CrossRefGoogle ScholarPubMed
Donohue, MC, Sperling, RA, Salmon, DP, et al. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol 2014; 71: 961–70. https://doi.org/10.1001/jamaneurol.2014.803.CrossRefGoogle ScholarPubMed
Blennow, K, Zetterberg, H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med 2018; 284: 643–63. https://doi.org/10.1111/joim.12816.Google Scholar
Ismail, R, Parbo, P, Madsen, LS, et al. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer’s disease: a longitudinal PET study. J Neuroinflammation 2020; 17: 151. https://doi.org/10.1186/s12974-020-01820-6.Google Scholar
Preische, O, Schultz, SA, Apel, A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019; 25: 277–83. https://doi.org/10.1038/s41591-018-0304-3.Google Scholar
Liu, W, Lin, H, He, X, et al. Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment. Transl Psychiatry 2020; 10: 125. https://doi.org/10.1038/s41398-020-0801-2.CrossRefGoogle ScholarPubMed
O’Brien, PC, Fleming, TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–56. https://doi.org/10.2307/2530245.Google ScholarPubMed
Lan, KKG, Demets, DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–63. https://doi.org/10.1093/biomet/70.3.659.CrossRefGoogle Scholar
Whitehead, J, Stratton, I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39: 227–36. https://doi.org/10.2307/2530822.Google Scholar
Hume, S, Aerts, J, Sarnikar, S, Huser, V. Current applications and future directions for the CDISC Operational Data Model standard: a methodological review. J Biomed Inform 2016; 60: 352–62. https://doi.org/10.1016/j.jbi.2016.02.016.Google Scholar
Hendrix, SB, Wilcock, GK. What we have learned from the Myriad trials. J Nutr Health Aging 2009; 13: 362–4. https://doi.org/10.1007/s12603-009-0044-7.Google Scholar
Hendrix, SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther 2012; 4: 24. https://doi.org/10.1186/alzrt127.Google Scholar
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER). Early Alzheimer’s disease: developing drugs for treatment. Guidance for industry. Available at: www.fda.gov/files/drugs/published/Alzheimer%E2%80%99s-Disease---Developing-Drugs-for-Treatment-Guidance-for-Industy.pdf (accessed January 20, 2021).Google Scholar
European Medicines Agency. Clinical investigation of medicines for the treatment of Alzheimer’s disease/ CPMP/EWP/553/1995. Available at: www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf (accessed January 20, 2021).Google Scholar